Medica Keeltabletten menthol

Hauptinformation

  • Handelsname:
  • Medica Keeltabletten menthol Lutschtablette gepresst 5 mg;1 mg
  • Dosierung:
  • 5 mg;1 mg
  • Darreichungsform:
  • Lutschtablette gepresst
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Medica Keeltabletten menthol Lutschtablette gepresst 5 mg;1 mg
    Belgien
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Oropharyngeale Ressourcen

Weitere Informationen

Status

  • Quelle:
  • AFMPS - Agence Fédérale des Médicaments et des Produits de Santé - Belgium
  • Zulassungsnummer:
  • BE172435
  • Letzte Änderung:
  • 12-04-2018

Packungsbeilage

GEBRAUCHSINFORMATION: INFORMATION FÜR ANWENDER

MEDICA HALSTABLETTEN MENTHOL, 5mg/1mg, Lutschtabletten, gepresst

Chlorhexidin Hydrochlorid - Lidocain Hydrochlorid

Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Anwendung dieses

Arzneimittels beginnen, denn sie enthält wichtige Informationen.

Wenden Sie dieses Arzneimittel immer genau wie in dieser Packungsbeilage beschrieben bzw genau nach

Anweisung Ihres Arztes oder Apothekers an.

Wass in dieser Packungsbeilage steht:

1. Was ist Medica Halstabletten Menthol und wofür wird es angewendet?

2. Was solten Sie vor der Anwendung von Medica Halstabletten Menthol beachten?

3. Wie ist Medica Halstabletten Menthol anzuwenden?

4. Welche Nebenwirkungen sind möglich?

5. Wie ist Medica Halstabletten Menthol aufzubewahren?

6. Inhalt der Packung und weitere Informationen.

1.

WAS IST MEDICA HALSTABLETTEN MENTHOL UND WOFÜR WIRD ES

ANGEWENDET?

Medica Halstabletten Menthol ist eine Lutschtablette für örtliche Anwendung in dem Mund und der

Rachenhöhle.

Es ist ein Desinfektionsmittel und örtliches schmerzstillendes Mittel.

Medica Halstabletten Menthol ist angezeigt bei:

Behandlung der Symptome von Halsschmerzen, roter Kehle, Erkrankungen der Rachenhöhle mit

Reizungen;

Im Fall einer bakteriellen Infektion mit Fieber ist eine ergänzende Behandlung erforderlich;

Medica Halstabletten Menthol enthält keinen Zucker und ist folglich auch für Diabetiker geeignet.

Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals

lesen.

Fragen Sie Ihren Apotheker, wenn Sie weitere Informationen oder einen Rat

benötigen.

Wenn Sie Nebenwurkungen bemerken, wenden Sie sich an Ihren Arzt oder

Apotheker. Dies gilt auch fur Nebenwirkungen, die nicht in dieser Packungsbeilage

angegeben sind.

Wenn Sie sich nach 3 bis 4 Tagen nicht besser oder gar schlechter fuhlen, wenden

Sie sich an Ihren Arzt.

GEBRAUCHSINFORMATION: INFORMATION FÜR ANWENDER

2.

WAS SOLTEN SIE VOR DER ANWENDUNG VON MEDICA HALSTABLETTEN

MENTHOL BEACHTEN?

Medica Halstabletten Menthol darf nicht angewendet werden,

Wenn Sie allergisch gegen Chlorhexidin Hydrochlorid oder Lidocain Hydrochlorid oder einen der

in Abschnitt 6. genannten sonstigen Bestandteile von Medica Halstabletten Menthol sind.

Bei Kindern unter 6 Jahren.

Warnhinweise und Vorsichtsmaßnahmen

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker, bevor Sie Medica Halstabletten Menthol

anwenden.

Medica Halstabletten Menthol darf nicht langanhaltend, ununterbrochen oder immer wieder

verwendet werden. Beschränken Sie den Gebrauch lediglich auf die notwendige Erleichterung

von Schmerz und Irritation.

Wenn eine zu hohe Dosis verwendet wird (mehr als 20 Tabletten pro Tag), besteht ein geringes

Risiko zur Verringerung der Kontrolle des Schluckreflexes.

Bei Kleinkindern, die schon einen Anfall von Konvulsionen gehabt haben. Dieses Arzneimittel

enthält nämlich Menthol.

Wenn Sie noch andere Arzneimittel anwenden. Bitte lesen Sie auch die Rubrik: „Anwendung von

Medica Halstabletten Menthol zusammen mit anderen Arzneimitteln“.

Fragen Sie Ihren Arzt, wenn eine der obigen Warnungen auf Sie zutrifft oder dies in der

Vergangenheit der Fall war.

Kinder

Dieses Arzneimittel darf nicht bei Kindern unter 6 Jahren angewendet werden.

Anwendung von Medica Halstabletten Menthol zusammen mit anderen Arzneimitteln

Informieren Sie Ihren Arzt oder Apotheker wenn Sie andere Arzneimittel anwenden, kürzlich andere

Arzneimittel angewendet haben oder beabsichtigen andere Arzneimittel anzuwenden.

Nicht gleichzeitig mit Arzneimitteln für leichte Formen von Alzheimer

(Cholinesterasehemmern) anwenden.

Nicht gleichzeitig mit anderen Desinfektionsmitteln anwenden.

Anwendung von Medica Halstabletten Menthol

zusammen mit Nahrungsmitteln und

Getränken

Keine besonderen Vorsichtsmaßnahmen erforderlich.

Schwangerschaft und Stillzeit

Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger zu sein oder

beabsichtigen, schwanger zu werden, fragen Sie vor der Anwendung dieses Arzneimittels Ihren Arzt

oder Apotheker um Rat.

Wenn Sie die vorangegangenen Vorsichtsmaßnahmen respektiert, können Sie Medica Halstabletten

Menthol während der Schwangerschaft und der Stillzeit benutzen. Informieren Sie Ihren Arzt über

die Benutzung dieses Arzneimittels.

GEBRAUCHSINFORMATION: INFORMATION FÜR ANWENDER

Verkehrstüchtigkeit und Fähigkeit zum Bedienen von Maschinen

Keine besonderen Vorsichtsmaßnahmen erforderlich.

Medica Halstabletten Menthol enthält Menthol und Sorbitol

Medica Halstabletten Menthol enthält Menthol: Vorsicht bei Kleinkindern, die schon einen Anfall

von Konvulsionen gehabt haben.

Medica Halstabletten Menthol enthält Sorbitol. Bitte nehmen Sie Medica Halstabletten Menthol erst

nach Rücksprache mit Ihrem Arzt ein, wenn Ihnen bekannt ist, dass Sie unter einer

Zuckerunverträglichkeit leiden. Sorbitol kann einen leicht abführende Wirkung haben. Der

Kalorienwert beträgt 2,6 kcal/g Sorbitol.

3.

WIE IST MEDICA HALSTABLETTEN MENTHOL ANZUWENDEN?

Wenden Sie Medica Halstabletten Menthol immer genau nach Absprache mit Ihrem Arzt oder

Apotheker an. Fragen Sie bei Ihrem Arzt oder Apotheker nach, wenn Sie sich nicht sicher sind.

Die empfohlene Dosis beträgt:

Erwachsene: 6 bis 10 Tabletten pro Tag.

Kinder ab 6 Jahren: 3 bis 5 Tabletten pro Tag.

Die Tablette langsam im Mund auflutschen.

Dieses Arzneimittel darf nicht über einen längeren Zeitraum benutzt werden. Fragen Sie Ihren Arzt

um Rat, falls die Symptome verschlimmern oder nicht verbessern nach 3 bis 4 Tagen.

Wenn Sie eine größere Menge von Medica Halstabletten Menthol angewendet haben, als Sie

sollten

Wenn Sie eine größere Menge von Medica Halstabletten Menthol haben angewendet, kontaktieren Sie

sofort Ihren Arzt, Ihren Apotheker oder das Antigiftzentrum (070/245.245).

Dieses Arzneimittel enthält lediglich einen Bruchteil einer toxischen Dosis. Bei richtiger Anwendung

sind die Risiken auf eine Überdosierung sehr gering.

Symptome einer Überdosierung sind: Ruhelosigkeit, Ohrensausen, Atmungsschwierigkeiten,

Herzrhythmusstörungen, Verminderung der Kontrolle des Schluckreflexes.

Wenn Sie weitere Fragen zur Anwendung des Arzneimittels haben, wenden Sie sich an Ihren Arzt oder

Apotheker.

4.

WELCHE NEBENWIRKUNGEN SIND MÖGLICH?

Wie alle Arzneimittel kann auch Medica Halstabletten Menthol Nebenwirkungen haben, die aber

nicht bei jedem auftreten müssen.

Sehr selten: allergische Haut- und Schleimhautreaktionen.

Es kann zu Geschmacksstörungen, Brandgefühl auf der Zunge und ernstliche allergische

Reaktionen (anaphylaktischen Reaktionen) kommen.

Bei langanhaltender, ununterbrochener Anwendung kann eine Braunverfärbung der Zähne

auftreten. Diese Verfärbung ist jedoch leicht zu entfernen.

GEBRAUCHSINFORMATION: INFORMATION FÜR ANWENDER

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt auch

für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind.

5.

WIE IST MEDICA HALSTABLETTEN MENTHOL AUFZUBEWAHREN?

Bewahren Sie dieses Arzneimittel für Kinder unzugänglich auf. Nicht über 25°C lagern. Sie dürfen

Medica Halstabletten Menthol nach dem auf der Schachtel/der Blisterpackung

nach „EXP“

angegebenen Verfalldatum nicht mehr anwenden. Die ersten beiden Ziffern geben den Monat, die

folgenden zwei oder vier Ziffern das Jahr an. Das Verfalldatum bezieht sich auf den letzten Tag des

angegebenen Monats.

6.

INHALT DER PACKUNG UND WEITERE INFORMATIONEN.

Was Medica Halstabletten Menthol enthält

Die Wirkstoffe sind: Chlorhexidin Hydrochlorid 5 mg - Lidocain Hydrochlorid 1 mg.

Die sonstigen Bestandteile sind: Sorbitol – Magnesiumstearat – Zitronensäure, wasserfrei –

Menthol.

Wie Medica Halstabletten Menthol aussieht und Inhalt der Packung

Packung mit 40 Lutschtabletten, gepresst in Blisterpackung und Packung mit 36 Lutschtabletten,

gepresst in Folienstreifen.

Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht.

Pharmazeutischer Unternehmer und Hersteller

Laboratoria QUALIPHAR N.V./S.A. - Rijksweg 9 - 2880 Bornem - Belgien

Zulassungsnummer: BE172435

Art der Abgabe

Freie Abgabe.

Im selben Sortiment gibt es auch:

MEDICA HALSTABLETTEN LEMON, 5 mg/1 mg, Lutschtabletten, gepresst:

Desinfektionsmittel und örtliches schmerzstillendes Mittel für Mund und Rachenhöhle

MEDICA HALSSPRAY MENTHOL, 20 mg/10 ml; 5 mg/10 ml, Spray zur Anwendung in der

Mundhöhle: Desinfektionsmittel und örtliches schmerzstillendes Mittel für Mund und Rachenhöhle

MEDICA HALSSPRAY LEMON, 20 mg/10 ml; 5 mg/10 ml, Spray zur Anwendung in der

Mundhöhle: Desinfektionsmittel und örtliches schmerzstillendes Mittel für Mund und Rachenhöhle

Diese Packungsbeilage wurde zuletzt überarbeitet im 11/2012.

Diese Packungsbeilage wurde zuletzt genehmigt im 11/2012

24-9-2018

FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases

FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases

FDA has awarded 12 new clinical trial research grants to enhance the development of medical products for patients with rare diseases

FDA - U.S. Food and Drug Administration

19-9-2018

September 19, 2018: Springfield Doctor Sentenced for Illegally Sharing Patient Medical Files

September 19, 2018: Springfield Doctor Sentenced for Illegally Sharing Patient Medical Files

September 19, 2018: Springfield Doctor Sentenced for Illegally Sharing Patient Medical Files

FDA - U.S. Food and Drug Administration

18-9-2018

FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications

FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications

FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications.

FDA - U.S. Food and Drug Administration

14-9-2018

FDA Releases Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings

FDA Releases Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings

CVM’s five-year action plan for supporting antimicrobial stewardship in veterinary settings builds upon the important steps CVM has taken to eliminate production uses of medically important antimicrobials.

FDA - U.S. Food and Drug Administration

12-9-2018

FDA awards five grants to advance the development of pediatric medical devices

FDA awards five grants to advance the development of pediatric medical devices

FDA has awarded grants to five Pediatric Device Consortia that will provide advice to innovators of children's medical devices

FDA - U.S. Food and Drug Administration

12-9-2018

Natural Disaster Preparedness and Response (Drugs)

Natural Disaster Preparedness and Response (Drugs)

The FDA reminds consumers to have an emergency plan and to take precautions for storing water and ensuring the safety of their food and medical supplies for themselves and their pets during and after severe storms (tornados, hurricanes, blizzards) and other events that can result in power outages, flooding, or road and business closures.

FDA - U.S. Food and Drug Administration

11-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom

Statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom

Statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom

FDA - U.S. Food and Drug Administration

11-9-2018

Marvelon 28 birth control pills: Packages do not contain day-of-the-week stickers

Marvelon 28 birth control pills: Packages do not contain day-of-the-week stickers

Health Canada is informing Canadians that packages of certain lots of Marvelon 28 do not include day-of-the-week stickers. The stickers are meant to be applied on the blister pack containing the pills. The stickers indicate the first day of the week when the medication is started, and the weekdays that the pills should be taken. The stickers may be used by women to help them remember if they took their daily pill on a given day. Without these stickers, there may be an increased chance of missing a dose.

Health Canada

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

10-9-2018

"My Medicines" ... This Brochure Can be a Lifesaver

"My Medicines" ... This Brochure Can be a Lifesaver

"My Medicines" a brochure offered by FDA's Office of Women's Health, can play a vital role in the medical treatment you receive during an emergency.

FDA - U.S. Food and Drug Administration

30-8-2018

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Denmark and EFSA – Final report

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Denmark and EFSA – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 During the project seven standard operating procedures (SOP) were developed for the four data domains (zoonoses, chemical contaminant, pesticide residues and veterinary medical products residues). The SOPs describe 1) How the national governance of risk assessment data is organised, 2) how data are collected and validated before delivering to EFSA covering all four domains, 3) How data is transferred to EFSA, 4) how to respond to EFSA request for clarificati...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.

FDA - U.S. Food and Drug Administration

23-8-2018

August 22, 2018: Louisiana Pharmacist Convicted of Trafficking and Selling Stolen Medication

August 22, 2018: Louisiana Pharmacist Convicted of Trafficking and Selling Stolen Medication

August 22, 2018: Louisiana Pharmacist Convicted of Trafficking and Selling Stolen Medication

FDA - U.S. Food and Drug Administration

23-8-2018

Rote-Hand-Brief zu THIOPENTAL ROTEXMEDICA 500 mg und THIOPENTAL ROTEXMEDICA 1000 mg vom 15.08.2018

Rote-Hand-Brief zu THIOPENTAL ROTEXMEDICA 500 mg und THIOPENTAL ROTEXMEDICA 1000 mg vom 15.08.2018

Rote-Hand-Brief zu THIOPENTAL ROTEXMEDICA 500 mg und THIOPENTAL ROTEXMEDICA 1000 mg

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-8-2018

Dringende Sicherheitsinformation zu Transplant-Aspiration Needle, SPI-CUT von Somatex Medical Technologies GmbH / Berlin

Dringende Sicherheitsinformation zu Transplant-Aspiration Needle, SPI-CUT von Somatex Medical Technologies GmbH / Berlin

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-8-2018

Dringende Sicherheitsinformation zu Rotating IV pole von GE Healthcare Clinical Systems (Ohmeda Medical)

Dringende Sicherheitsinformation zu Rotating IV pole von GE Healthcare Clinical Systems (Ohmeda Medical)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-8-2018

Dringende Sicherheitsinformation zu power supply for div. sleep therapy devices von Löwenstein Medical Technology GmbH + Co. KG

Dringende Sicherheitsinformation zu power supply for div. sleep therapy devices von Löwenstein Medical Technology GmbH + Co. KG

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-8-2018

Dringende Sicherheitsinformation zu Allura Xper and Integris Allura Systems von Philips Medical Systems Nederland B.V.

Dringende Sicherheitsinformation zu Allura Xper and Integris Allura Systems von Philips Medical Systems Nederland B.V.

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-8-2018

Dringende Sicherheitsinformation zu MobileDiagnost wDR von Philips Medical Systems DMC GmbH

Dringende Sicherheitsinformation zu MobileDiagnost wDR von Philips Medical Systems DMC GmbH

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-8-2018

Dringende Sicherheitsinformation zu RYTHMIC EVOLUTION von MICREL MEDICAL DEVICES SA

Dringende Sicherheitsinformation zu RYTHMIC EVOLUTION von MICREL MEDICAL DEVICES SA

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

20-8-2018

Danish Medicines Agency lands new European chairmanship

Danish Medicines Agency lands new European chairmanship

Nikolai Brun, Director of Medical Evaluation & Biostatistics, has been elected chair of the Task Force on Big Data in the pharmaceutical area. The task force is a collaboration between the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) which is to identify advantages and challenges of using big data for the development of medicine.

Danish Medicines Agency

16-8-2018

Rote-Hand-Brief zu THIOPENTAL ROTEXMEDICA 500 mg und THIOPENTAL ROTEXMEDICA 1000 mg.

Rote-Hand-Brief zu THIOPENTAL ROTEXMEDICA 500 mg und THIOPENTAL ROTEXMEDICA 1000 mg.

Die Firma Rotexmedica GmbH Arzneimittelwerk möchte in Abstimmung mit dem Landesamt für soziale Dienste Schleswig-Holstein über die folgende vorsorgliche Einschränkung der Anwendung auf strenge Indikationsstellungen sowie eine Vertriebseinschränkung auf Krankenhäuser und Kliniken für die Produkte THIOPENTAL ROTEXMEDICA 500 mg und 1000 mg, Pulver zur Herstellung einer Infusionslösung, informieren.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

FDA approves new treatment for a rare genetic disorder, Fabry disease

FDA approves new treatment for a rare genetic disorder, Fabry disease

FDA approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

FDA - U.S. Food and Drug Administration

10-8-2018

Dringende Sicherheitsinformation zu Philips SureSigns VS & VM Monitors, and View Stati von Philips Medical Systems

Dringende Sicherheitsinformation zu Philips SureSigns VS & VM Monitors, and View Stati von Philips Medical Systems

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

Dringende Sicherheitsinformation zu M300 von Draeger Medical Systems, Inc

Dringende Sicherheitsinformation zu M300 von Draeger Medical Systems, Inc

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

10-8-2018

Dringende Sicherheitsinformation zu Rusch Green Lite (MAC 3) von Teleflex Medical Athlone

Dringende Sicherheitsinformation zu Rusch Green Lite (MAC 3) von Teleflex Medical Athlone

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

6-8-2018

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment drugs to treat opioid use disorder.

FDA - U.S. Food and Drug Administration

3-8-2018

HP Hood LLC Recalls Select Units of Half-Gallon Refrigerated Vanilla Almond Breeze Almond Milk due to Possible Milk Allergen

HP Hood LLC Recalls Select Units of Half-Gallon Refrigerated Vanilla Almond Breeze Almond Milk due to Possible Milk Allergen

HP Hood LLC is voluntarily recalling a limited number of half-gallon (1.89 L) cartons of refrigerated Vanilla Almond Breeze almond milk because the product may contain milk, an allergen not listed on the label. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products. The product is safe to consume unless you have a milk allergy or sensitivity. To date, there has been one report of an allergic reaction. Medical ...

FDA - U.S. Food and Drug Administration

2-8-2018

Dringende Sicherheitsinformation zu Pessar - Panpac Medical Corporation von Panpac Medical Corporation

Dringende Sicherheitsinformation zu Pessar - Panpac Medical Corporation von Panpac Medical Corporation

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

21-9-2018

Click the link for a handy list of #FDA’s recommendations for using and  caring for your medical devices during a #hurricane.   https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity: https://go.usa.gov/xPbYt 

FDA - U.S. Food and Drug Administration

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

19-9-2018

 Important medical event terms list version 21.0 (IME-List)

Important medical event terms list version 21.0 (IME-List)

Europe - EMA - European Medicines Agency

17-9-2018

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid u

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid u

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid use disorder. #FDA

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here:  https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

FDA - U.S. Food and Drug Administration

14-9-2018

#FDA awards five grants to advance the development of pediatric medical devices. Click the link to read more about the grants and the FDA's work to advance the development of pediatric #MedicalDevices:  http://go.usa.gov/xPg2A 

#FDA awards five grants to advance the development of pediatric medical devices. Click the link to read more about the grants and the FDA's work to advance the development of pediatric #MedicalDevices: http://go.usa.gov/xPg2A 

#FDA awards five grants to advance the development of pediatric medical devices. Click the link to read more about the grants and the FDA's work to advance the development of pediatric #MedicalDevices: http://go.usa.gov/xPg2A 

FDA - U.S. Food and Drug Administration

6-9-2018

#FDA is launching the Quality in 510(k) Review Program Pilot to help promote efficiency and consistency in the review of certain moderate-risk medical devices. Click the link to find out more information about this new program:  https://go.usa.gov/xPxVa 

#FDA is launching the Quality in 510(k) Review Program Pilot to help promote efficiency and consistency in the review of certain moderate-risk medical devices. Click the link to find out more information about this new program: https://go.usa.gov/xPxVa 

#FDA is launching the Quality in 510(k) Review Program Pilot to help promote efficiency and consistency in the review of certain moderate-risk medical devices. Click the link to find out more information about this new program: https://go.usa.gov/xPxVa  #MedicalDevice pic.twitter.com/dOcFpbed9K

FDA - U.S. Food and Drug Administration

5-9-2018

Patients may not have access to an #FDA approved or cleared device in the absence of adequate coverage. That’s why we’re expanding our work with private payors to help narrow the time it takes for payors to make a coverage determination on new medical dev

Patients may not have access to an #FDA approved or cleared device in the absence of adequate coverage. That’s why we’re expanding our work with private payors to help narrow the time it takes for payors to make a coverage determination on new medical dev

Patients may not have access to an #FDA approved or cleared device in the absence of adequate coverage. That’s why we’re expanding our work with private payors to help narrow the time it takes for payors to make a coverage determination on new medical devices

FDA - U.S. Food and Drug Administration

5-9-2018

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations  https:

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https:

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https://go.usa.gov/xPcyB 

FDA - U.S. Food and Drug Administration

5-9-2018

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medica

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medica

FDA's Center for Devices and Radiological Health, along with the University of Maryland Center of Excellence in Regulatory Science and Innovation will be hosting a workshop on #PatientEngagement in Real-World Evidence Lessons and Best Practices for medical devices on Sept. 9th

FDA - U.S. Food and Drug Administration

4-9-2018

Certificates of free sale and export certificates for medical devices

Certificates of free sale and export certificates for medical devices

The TGA has introduced a new process for certificates of free sale and export certificates.

Therapeutic Goods Administration - Australia

20-8-2018

Comparable overseas regulators for medical device applications

Comparable overseas regulators for medical device applications

Use of market authorisation evidence from comparable overseas regulators for medical devices

Therapeutic Goods Administration - Australia

20-8-2018

Application requirements for medical devices - preliminary assessment

Application requirements for medical devices - preliminary assessment

Applications for the inclusion of medical devices (including IVDs) in the ARTG must meet certain requirements in order to pass preliminary assessment

Therapeutic Goods Administration - Australia

15-8-2018

Electronic Instructions for Use - eIFU

Electronic Instructions for Use - eIFU

New guidance on electronic instructions for use for medical devices

Therapeutic Goods Administration - Australia

14-8-2018

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at  https://go.usa.gov/xUF39   #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kids #MedicalDevice pic.twitter.com/XGwlpgopGn

FDA - U.S. Food and Drug Administration

14-8-2018

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization.  https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevicepic.twitter.com/bMYgjX8CTX

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization. https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevicepic.twitter.com/bMYgjX8CTX

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization. https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevice pic.twitter.com/bMYgjX8CTX

FDA - U.S. Food and Drug Administration

14-8-2018

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting.  We look forward to continuing discussions around increasing medical device options for children today.  #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #MedicalDevice pic.twitter.com/7cXPFfvfif

FDA - U.S. Food and Drug Administration

14-8-2018

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting  #devices4kids #FDA #MedicalDevicepic.twitter.com/0I1Poe9Yqn

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting #devices4kids #FDA #MedicalDevicepic.twitter.com/0I1Poe9Yqn

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting #devices4kids #FDA #MedicalDevice pic.twitter.com/0I1Poe9Yqn

FDA - U.S. Food and Drug Administration

13-8-2018

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevice pic.twitter.com/mzlmU6Nq9U

FDA - U.S. Food and Drug Administration

13-8-2018

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCertpic.twitter.com/X4wQbX0Tjc

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCertpic.twitter.com/X4wQbX0Tjc

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCert pic.twitter.com/X4wQbX0Tjc

FDA - U.S. Food and Drug Administration

13-8-2018

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation.  https://go.usa.gov/xU6rg 
#devices4kids #Pediatricspic.twitter

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation. https://go.usa.gov/xU6rg  #devices4kids #Pediatricspic.twitter

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation. https://go.usa.gov/xU6rg  #devices4kids #Pediatrics pic.twitter.com/3tXTgwPJPo

FDA - U.S. Food and Drug Administration

13-8-2018

IMDRF consultation: Principles of labelling for medical devices and IVD medical devices

IMDRF consultation: Principles of labelling for medical devices and IVD medical devices

The IMDRF is seeking comments on a proposed guidance document

Therapeutic Goods Administration - Australia

10-8-2018

Vyaire Medical, Inc. Recalls AirLife Resuscitation Devices Due to Manufacturing Error Preventing Oxygen Delivery  https://go.usa.gov/xUHgr  #fda #medicaldevice

Vyaire Medical, Inc. Recalls AirLife Resuscitation Devices Due to Manufacturing Error Preventing Oxygen Delivery https://go.usa.gov/xUHgr  #fda #medicaldevice

Vyaire Medical, Inc. Recalls AirLife Resuscitation Devices Due to Manufacturing Error Preventing Oxygen Delivery https://go.usa.gov/xUHgr  #fda #medicaldevice

FDA - U.S. Food and Drug Administration

10-8-2018

Medical devices post-market vigilance - statistics for 2017

Medical devices post-market vigilance - statistics for 2017

Post-market vigilance statistics for 2017

Therapeutic Goods Administration - Australia

7-8-2018

Novem (Boehringer Ingelheim Vetmedica GmbH)

Novem (Boehringer Ingelheim Vetmedica GmbH)

Novem (Active substance: Meloxicam) - Centralised - Yearly update - Commission Decision (2018)5413 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

ACMD meeting statement, Meeting 40, 12 April 2018

ACMD meeting statement, Meeting 40, 12 April 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

7-8-2018

ACMD meeting statement, Meeting 41, 28 June 2018

ACMD meeting statement, Meeting 41, 28 June 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

7-8-2018

Research: Software as a Medical Device and Cyber Security for Medical Devices

Research: Software as a Medical Device and Cyber Security for Medical Devices

Opportunity to participate in CSIRO research to inform new Australian medical device industry guidance

Therapeutic Goods Administration - Australia

6-8-2018

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice  https://go.usa.gov/xUvBD pic.twitter.com/mWuQWK9MLk

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice https://go.usa.gov/xUvBD pic.twitter.com/mWuQWK9MLk

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice https://go.usa.gov/xUvBD  pic.twitter.com/mWuQWK9MLk

FDA - U.S. Food and Drug Administration

2-8-2018

Pinimenthol® Erkältungssalbe

Rote - Liste